<DOC>
	<DOCNO>NCT02001519</DOCNO>
	<brief_summary>Achievement pathologic complete response important prognosticator predict long term outcome triple negative cancer . The efficacy add 4 cycle cisplatin ( CDDP4 ) investigate whether addtional pathologic complete response achieve triple negative breast cancer patient recieved 4 cycle adriamycin cyclophosphamide ( AC4 ) reach clinical complete response course neoadjuvant therapy .</brief_summary>
	<brief_title>Additional 4 Cycles Cisplatin ( CDDP4 ) Patients With Triple Negative Breast Cancer Neoadjuvant Chemotherapy</brief_title>
	<detailed_description>First outcome measure ( analysis ) : time surgery , Second outcome measure : 2019 August , 5 year Overall Survival , Disease free survival</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Patients histologically proven breast cancer 2 . Age , least 20 year 3 . ER/PR/HER2 ( negative/negative/negative ER/PR negative : nuclear reaction &lt; 1 % , Allred score 0 2 HER2 negative : HER2 ; IHC ( immunohistochemistry ) 0,1+ FISH/SISH ( ) case IHC 2+ 4 . Clinically stage II III histologically proven lymphnode involvement ( T &gt; 1.5 cm lymph node [ LN ] &gt; 1.5 cm ) 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 6 . No prior hormonal treatment , chemotherapy radiotherapy allow . 7 . Adequate hematologic , liver kidney function 8 . Written inform consent 1 . Pregnancy lactation 2 . Prior chemotherapy radiotherapy malignancy 3 . Stage T4d ; inflammatory breast cancer 4 . No primary tumor ( T0 ) 5 . Documented history cardiac disease contraindicate anthracyclines 6 . Currently active infection</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>